{"product_id":"prqr-vrio-analysis","title":"ProQR Therapeutics N.V. (PRQR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to sustained success, this VRIO analysis distills the core competitive advantage of ProQR Therapeutics N.V. (PRQR) - are its resources truly Valuable, Rare, Inimitable, and Organized? Read on to uncover the definitive assessment of its market power and what it means for its future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 1. Axiomer RNA Editing Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of ProQR Therapeutics N.V., the Axiomer RNA Editing Platform. This isn't just theory anymore; the company is actively moving this technology into human trials, which is the acid test for any platform in this space. My take is that if the initial human data from the lead program comes in clean, this platform has the makings of a truly differentiated, long-term advantage.\u003c\/p\u003e\n\n\u003cp\u003eThe platform itself is designed to be a next-generation approach, using the cell’s own ADAR (Adenosine Deaminase Acting on RNA) machinery to make precise, single-nucleotide edits in RNA using what they call Editing Oligonucleotides (EONs). This is a key distinction from other RNA approaches. It’s about recruiting the body’s natural tools for a targeted fix.\u003c\/p\u003e\n\n\u003ch\u003eValue Assessment\u003c\/h\u003e\n\u003cp\u003eThe platform is definitely valuable because it addresses a huge need: creating a new class of medicines capable of precise, single-nucleotide correction in RNA. This has the potential to treat diseases currently considered untreatable. The lead program, AX-0810, targeting NTCP for cholestatic diseases, is the proof point here. The company is organized to execute on this value, having submitted the Clinical Trial Application (CTA) for AX-0810 in Q2 2025.\u003c\/p\u003e\n\u003cp\u003eHere are some key execution metrics as of late 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCTA submission for AX-0810: Q2 2025.\u003c\/li\u003e\n\u003cli\u003eInitial safety\/PK data expected by year-end 2025.\u003c\/li\u003e\n\u003cli\u003eCash position as of September 30, 2025: €106.9 million.\u003c\/li\u003e\n\u003cli\u003ePipeline includes CNS applications like AX-2402 for Rett Syndrome.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding takes 14+ days, churn risk rises - similarly, if clinical enrollment stalls, the timeline for value realization gets pushed out.\u003c\/p\u003e\n\n\u003ch\u003eRarity Assessment\u003c\/h\u003e\n\u003cp\u003eThe rarity hinges on the specific execution: ADAR-mediated RNA editing via EONs. While other RNA modalities exist, ProQR Therapeutics is the first to get this specific mechanism into the clinic, which is a rare feat. They are advancing this across both liver and CNS programs. This first-mover status in clinical development for this specific approach gives them a temporary leg up in mindshare and data generation.\u003c\/p\u003e\n\n\u003ch\u003eImitability Assessment\u003c\/h\u003e\n\u003cp\u003eImitability is where the platform builds a moat, assuming the science holds up. The core mechanism is protected by what is described as a strong, defended patent estate. To be fair, in biotech, patents are the first line of defense, but they are critical. Direct imitation without infringement would be very difficult, especially given the lead candidate is already in a Phase 1 study, which builds process know-how that is hard to copy.\u003c\/p\u003e\n\n\u003ch\u003eOrganization Assessment\u003c\/h\u003e\n\u003cp\u003eThe organization looks geared for the clinical stage. You see this in the recent leadership changes - appointing a new Chief Financial Officer and Chief Medical Officer in April 2025 to shepherd the platform through trials. They have a clear plan: Q2 2025 CTA, Q4 2025 initial data readout, and a partnership with Eli Lilly that provides significant non-dilutive potential, valued up to $3.9 billion. The €106.9 million cash position as of Q3 2025 provides runway into mid-2027, showing they are organized to fund operations through key near-term inflection points.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on their financial footing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (as of Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€106.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRunway into mid-2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€33.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects R\u0026amp;D investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Costs (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€34.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInvestment in platform advancement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage Evaluation\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e. It’s temporary because the platform has not yet proven its safety and efficacy profile in humans. If the Q4 2025 data readout for AX-0810 is positive, and subsequent trials confirm efficacy, the combination of proprietary ADAR-mediated editing, strong IP, and first-in-human data will likely elevate this to a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eVRIO Scoring Summary\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePlatform enables a novel, precise therapeutic modality.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSpecific ADAR-mediated EON approach is novel in clinical stage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eProtected by a strong, defended patent estate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eStructured for clinical execution with key hires and funding runway.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAwaits human clinical validation data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 2. Defended Intellectual Property Estate\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a legal moat around the core Axiomer technology, protecting future revenue streams from direct competition. The technology fundamentally covers the use of an oligonucleotide to recruit endogenous deaminating enzymes in the cell, with invention dating back to 2014.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs have IP, but ProQR has successfully defended its key platform patents against opposition in major jurisdictions like Europe and Japan. As of April 2024, ProQR has extensive patent protection related to its Axiomer RNA editing platform, including 15 published patent families that currently comprise a total of 28 patents.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very High. Competitors face significant legal hurdles and the risk of litigation to replicate the core concept, as evidenced by multiple successful defenses against third-party oppositions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company actively defends its IP, showing commitment to safeguarding this asset, supported by a cash position of approximately € 106.9 million as of September 30, 2025, providing runway into mid-2027. Research and development costs for the nine months ended September 30, 2025, were € 34.8 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the foundational patents remain valid.\u003c\/p\u003e\n\u003cp\u003eThe defense history validates the strength and broad scope of the IP estate:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003ePatent\/Reference\u003c\/th\u003e\n\u003cth\u003eDecision Date\/Event\u003c\/th\u003e\n\u003cth\u003eOutcome\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Patent Office (EPO)\u003c\/td\u003e\n\u003ctd\u003eEP 3 507 366 B1\u003c\/td\u003e\n\u003ctd\u003eApril 17, 2024\u003c\/td\u003e\n\u003ctd\u003eSuccessfully Defended\/Maintained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Patent Office (EPO)\u003c\/td\u003e\n\u003ctd\u003eEP 3234134 B1\u003c\/td\u003e\n\u003ctd\u003eMarch 7-8, 2023\u003c\/td\u003e\n\u003ctd\u003eSuccessfully Defended (after minor amendment)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapanese Patent Office (JPO)\u003c\/td\u003e\n\u003ctd\u003eJP 7244922\u003c\/td\u003e\n\u003ctd\u003eFebruary 2024\u003c\/td\u003e\n\u003ctd\u003eOpposition Rejected\/Maintained as Granted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States (USPTO)\u003c\/td\u003e\n\u003ctd\u003eUS Patent No. 11,781,134\u003c\/td\u003e\n\u003ctd\u003eGranted: November 2023\u003c\/td\u003e\n\u003ctd\u003eNew Grant Expanding Protection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe protected claims cover broad platform concepts, such as:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAn antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell.\u003c\/li\u003e\n\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe broad concept of applying endogenous ADAR by administering antisense oligonucleotides for RNA editing.\u003c\/li\u003e\n\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 3. Lead Clinical Asset (AX-0810) and Data Readout Timing\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e AX-0810, targeting NTCP for cholestatic diseases, is the first-in-human test of the platform, with potential to validate the entire technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Other firms have RNA therapies, but this is the first clinical test of ProQR’s specific ADAR editing approach.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors cannot easily replicate a program that is already in Phase 1, especially with human genetics support.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCTA Submission for AX-0810\u003c\/td\u003e\n\u003ctd\u003eSubmission to EMA\u003c\/td\u003e\n\u003ctd\u003eJune 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Phase 1 Data Expected\u003c\/td\u003e\n\u003ctd\u003eInitial safety\/PK data\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€119.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003emid-2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on Q2 2025 position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLilly Milestone Payment Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Costs (H1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€23.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst half of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (H1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€22.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst half of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The CTA was submitted in Q2 2025, and initial safety\/PK data for Cohort 1 is expected toward the end of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage hinges entirely on positive data; success creates a sustained advantage, failure erodes it quickly.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 4. Strategic Collaboration with Eli Lilly\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides external validation of the technology and offers non-dilutive funding through milestone payments, such as the \\$2.0 million earned in the first half of 2025, which was approximately €1.8 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Partnerships are common, but a collaboration with a major player like Eli Lilly on a novel platform is a significant endorsement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The specific terms and ongoing relationship are unique to ProQR.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The partnership is actively managed, contributing to the cash position and pipeline advancement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The value is sustained only as long as the partnership remains active and productive.\u003c\/p\u003e\n\u003cp\u003eThe collaboration, active since 2021, leverages ProQR's proprietary Axiomer™ RNA editing platform.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\/Term\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 Milestone Payment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$2.0 million\u003c\/strong\u003e (~\u003cstrong\u003e€1.8 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eFirst half of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Expansion Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOption to expand to a total of \u003cstrong\u003e15 targets\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones (Cumulative)\u003c\/td\u003e\n\u003ctd\u003eUp to nearly \u003cstrong\u003e\\$3.75bn\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eResearch, development, and commercialization milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Upfront\/Equity Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnder the expanded agreement (from 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e€119.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe partnership's structure includes options for expansion and access to delivery technology:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe agreement includes an option for Lilly to expand to a total of \u003cstrong\u003e15 targets\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpansion to \u003cstrong\u003e15 targets\u003c\/strong\u003e would trigger an additional \u003cstrong\u003e\\$50 million\u003c\/strong\u003e opt-in payment to ProQR.\u003c\/li\u003e\n\u003cli\u003eThe collaboration focuses on discovery, development, and commercialization of medicines for genetic disorders, targeting the liver and nervous system.\u003c\/li\u003e\n\u003cli\u003eLilly also holds the option to grant ProQR access to its delivery technology for ProQR's fully owned pipeline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial impact on operations for the first half of 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) costs were \u003cstrong\u003e€23.7 million\u003c\/strong\u003e for the six-month period ended June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities was \u003cstrong\u003e€27.2 million\u003c\/strong\u003e for the six-month period ended June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 5. Financial Runway (Cash Position)\n\u003c\/h2\u003e\n\u003cp\u003e\nThe financial runway is assessed based on the current cash position relative to operational expenditure, providing the duration for funding ongoing clinical development and operations.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue as of September 30, 2025\u003c\/th\u003e\n\u003cth\u003eComparative Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€106.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e€149.4 million (as of December 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities (9 Months Ended)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€39.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e€27.0 million (for the same period in 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Costs (9 Months Ended)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€34.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e€25.7 million (for the same period in 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Income from Eli Lilly (9 Months Ended)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.0 million\u003c\/strong\u003e (~\u003cstrong\u003e€1.8 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Financial Runway\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eInto mid-2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nVRIO Assessment Components:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eValue\u003c\/h5\u003e\n\u003cp\u003e\nProvides the necessary capital to fund operations and clinical trials without immediate need for dilutive financing.\n\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRarity\u003c\/h5\u003e\n\u003cp\u003e\nLow. Many clinical-stage biotechs have cash reserves.\n\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eImitability\u003c\/h5\u003e\n\u003cp\u003e\nLow. Cash is fungible, but the amount is specific.\n\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eOrganization\u003c\/h5\u003e\n\u003cp\u003e\nHigh. At September 30, 2025, the company held \u003cstrong\u003e€106.9 million\u003c\/strong\u003e in cash, providing runway into \u003cstrong\u003emid-2027\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eCompetitive Advantage\u003c\/h5\u003e\n\u003cp\u003e\nTemporary. This runway is finite; it buys time but doesn't create intrinsic value beyond operational stability.\n\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nAdditional Financial Context:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nNet loss for the nine-month period ended September 30, 2025, was \u003cstrong\u003e€33.3 million\u003c\/strong\u003e, or \u003cstrong\u003e€0.32\u003c\/strong\u003e per diluted share.\n\u003c\/li\u003e\n\u003cli\u003e\nGeneral and administrative costs for the nine-month period ended September 30, 2025, were \u003cstrong\u003e€11.2 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 6. Multi-Application Platform Versatility\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The Axiomer platform's design supports three distinct applications: modulate, correct, and protect, which expands the addressable market beyond a single indication. The lead program, AX-0810, targets Cholestatic Diseases, with an estimated population of approximately 100,000 people affected with Primary Sclerosing Cholangitis and Biliary atresia in the US and EU5.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Platform technologies are highly sought after. ProQR’s specific ADAR-editing versatility across multiple functions is a key differentiator. The company's intellectual property estate for ADAR-mediated RNA editing has been upheld when challenged in various jurisdictions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Replicating the platform's demonstrated ability to reliably execute all three functions (modulate, correct, protect) presents a significant challenge. The platform has demonstrated \u003cem\u003ein vivo\u003c\/em\u003e proof of target engagement leading to significant biomarker changes in non-human primates for AX-0810.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The pipeline demonstrates organizational commitment across different applications. As of the end of Q2 2025, ProQR held €119.8 million in cash and cash equivalents, providing a financial runway into mid-2027. The company is executing on a strategic partnership with Eli Lilly, which includes an option for expansion to a total of 15 targets for a $50 million opt-in payment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A versatile platform provides multiple avenues for value realization, supported by a strong financial position and strategic collaborations.\u003c\/p\u003e\n\u003cp\u003eThe pipeline programs illustrate the platform's versatility:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAX-0810: Cholestatic Diseases (NTCP target), designed to introduce a loss of function (LOF) variant. CTA submission occurred in Q2 2025, with initial clinical data anticipated in Q4 2025.\u003c\/li\u003e\n\u003cli\u003eAX-2402: Rett Syndrome (MECP2 R270X target), focused on correction to restore normal protein function. Advancement towards clinical candidate selection in 2025. This program is supported by a partnership with the Rett Syndrome Research Trust, securing up to $9.2 million.\u003c\/li\u003e\n\u003cli\u003eAX-2911: Metabolic Dysfunction-Associated Steatohepatitis (MASH) (PNPLA3 target), leveraging modulation of protein activity. Expected to select a clinical candidate in 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePlatform execution is reflected in financial investment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric \/ Program Detail\u003c\/th\u003e\n\u003cth\u003eValue \/ Status\u003c\/th\u003e\n\u003cth\u003eDate \/ Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€119.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€132.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€149.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly Partnership Expansion Option\u003c\/td\u003e\n\u003ctd\u003e15 total targets for $50 million opt-in payment\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly Milestone Income Recognized\u003c\/td\u003e\n\u003ctd\u003e$2.0 million (~€1.8 million)\u003c\/td\u003e\n\u003ctd\u003eFirst nine months of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRSRT Partnership Funding Secured for AX-2402\u003c\/td\u003e\n\u003ctd\u003eUp to $9.2 million\u003c\/td\u003e\n\u003ctd\u003eAs of Dec 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAX-0810 First Clinical Data Readout Anticipated\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Costs (Six Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€23.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnded June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe platform's potential is further supported by the expectation of up to four clinical data readouts across multiple programs in 2025 and 2026.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 7. Hepatocyte Delivery Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Proven ability to effectively deliver RNA therapies to liver cells (hepatocytes), which is crucial for treating many liver-based genetic disorders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Specific, proven in vivo delivery to the liver is a known hurdle in the RNA space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. While delivery is a known challenge, ProQR has demonstrated success with its existing technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. This expertise underpins the AX-0810 program, which targets the liver protein NTCP.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Delivery methods can be superseded by new technologies, but current proven success is valuable now.\u003c\/p\u003e\n\u003cp\u003eThe hepatocyte delivery expertise is demonstrated through the lead program AX-0810, which targets the sodium (Na+)-taurocholate cotransporting polypeptide (NTCP) in liver cells to treat cholestatic diseases.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTCP Editing Level (NHP Liver)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUp to 29%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAchieved with EON1 (early generation) after a single dose.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSerum Biomarker Bile Acids Change (NHP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8-fold change\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObserved \u003cstrong\u003e72 hours\u003c\/strong\u003e after treatment, correlating with editing levels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorrelation (Editing vs. Biomarker Change)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eR\u003csup\u003e2\u003c\/sup\u003e = 0.51\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported correlation between editing levels of NTCP and bile acids change in the serum in NHP in vivo.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCTA Submission Date for AX-0810\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubmission to the European Medicines Agency (EMA) to initiate Phase 1 trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Clinical Data Anticipation (AX-0810)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnticipated initial safety, tolerability, and PK data from Cohort 1.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Engagement Data Anticipation (AX-0810)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eH1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected data from all cohorts of the Phase 1 study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial resources supporting the advancement of this platform:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of the end of Q3 2025: approximately \u003cstrong\u003e€ 106.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFinancial runway projected into \u003cstrong\u003emid-2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) costs for the nine-month period ended September 30, 2025: \u003cstrong\u003e€ 34.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe AX-0810 program is designed to introduce a loss of function variant (NTCP Q68R) in the NTCP protein's RNA instructions, which naturally occurs in some individuals without clinical symptoms related to bile acid levels.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 8. Experienced Leadership Team\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides strategic direction and operational stability, especially during the transition to human trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Most public biotechs have experienced leaders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Specific individuals cannot be easily copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The team was recently strengthened with key appointments like the CFO and CMO in Q1 2025 to support growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Key personnel can leave, though institutional knowledge remains.\u003c\/p\u003e\n\u003cp\u003eThe leadership structure is supported by executives with significant tenure and financial\/clinical track records, as detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eAppointee\/Incumbent\u003c\/th\u003e\n\u003cth\u003eRelevant Experience\/Metric\u003c\/th\u003e\n\u003cth\u003eContext Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounder and CEO\u003c\/td\u003e\n\u003ctd\u003eDaniel A. de Boer\u003c\/td\u003e\n\u003ctd\u003eServing since incorporation in \u003cstrong\u003e2012\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Financial Officer (CFO)\u003c\/td\u003e\n\u003ctd\u003eDennis Hom\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e25 years\u003c\/strong\u003e of financial leadership; raised over \u003cstrong\u003e$4.5 billion\u003c\/strong\u003e in capital\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Medical Officer (CMO)\u003c\/td\u003e\n\u003ctd\u003eCristina Lopez Lopez, MD, PhD\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e20 years\u003c\/strong\u003e of global leadership in translational R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Scientific Officer (CSO)\u003c\/td\u003e\n\u003ctd\u003eGerard Platenburg, PhD\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e25 years\u003c\/strong\u003e of senior managerial experience\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManagement Team Average Tenure\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.9 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational strength is further evidenced by the financial resources and strategic partnerships managed by the team:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents were approximately \u003cstrong\u003e€ 106.9 million\u003c\/strong\u003e as of September 30, 2025, providing runway into \u003cstrong\u003emid-2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the nine-month period ended September 30, 2025, was \u003cstrong\u003e€ 39.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe strategic collaboration with Eli Lilly and Company is valued up to \u003cstrong\u003e$3.9 billion\u003c\/strong\u003e in upfront payments and milestones.\u003c\/li\u003e\n\u003cli\u003eThe CFO, Dennis Hom, previously executed transactions totaling over \u003cstrong\u003e$57 billion\u003c\/strong\u003e in disclosed value at prior roles.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProQR Therapeutics N.V. (PRQR) - VRIO Analysis: 9. Deep Rooting in Human Genetics\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eVRIO Analysis Component Assessment:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Pipeline programs are based on human genetics data, which increases the probability that modulating a target will have a meaningful clinical effect.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies use genetics, but ProQR emphasizes this as a core tenet for high unmet need targets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The specific genetic targets selected for the pipeline are proprietary decisions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. This principle guides pipeline selection, focusing on diseases with high unmet need.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A genetics-first approach is a long-term strategic advantage in drug development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePipeline Programs Rooted in Human Genetics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAX-0810 (Cholestatic Diseases targeting NTCP):\u003c\/strong\u003e Designed to introduce a loss of function (LOF) variant found in human genetics to prevent bile acid reuptake in the liver. Primary sclerosing cholangitis (PSC) and biliary atresia (BA) are forms of this disease where currently there are no approved drugs. Preclinical data showed up to 29% editing of NTCP in non-human primates (NHPs) after a single dose, leading to an 8-fold change in the serum biomarker bile acids.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAX-2402 (Rett Syndrome targeting MECP2):\u003c\/strong\u003e Being developed for individuals with the R270X mutation in the MECP2 gene. Rett Syndrome is a progressive neurodevelopmental disorder affecting approximately 350,000 people worldwide, predominantly females, with no current cures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAX-1412 (Cardiovascular Disease targeting B4GALT1):\u003c\/strong\u003e Introduces a variant into B4GALT1 that is associated in human genetics with a significantly lower chance of developing cardiovascular disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: Cash Position and Operating Burn (Based on Q3 2025 Data)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe starting cash balance for the view is the Q3 2025 balance. The nine-month operating cash usage provides context for recent burn rate.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Starting Point)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€ 106.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€ 39.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€ 33.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Costs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€ 34.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eHypothetical 13-Week Cash Flow View (Incorporating Q3 End Balance):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek Ending\u003c\/td\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003eNet Cash Flow (Estimate\/Proxy)\u003c\/td\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1 (Hypothetical Start)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€ 106.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13 (Hypothetical End)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003ctd\u003e(Cannot be provided without guessing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516232753301,"sku":"prqr-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/prqr-vrio-analysis.png?v=1740207961","url":"https:\/\/dcf-model.com\/products\/prqr-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}